| Stereochemistry | ABSOLUTE |
| Molecular Formula | C24H25ClN2O |
| Molecular Weight | 392.921 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1[C@H]2CC[C@@H]1[C@H]([C@H](C2)C3=CC=C(Cl)C=C3)C4=CC(=NO4)C5=CC=C(C)C=C5
InChI
InChIKey=AUXUFNHAVGIVDC-IKJKNFHUSA-N
InChI=1S/C24H25ClN2O/c1-15-3-5-17(6-4-15)21-14-23(28-26-21)24-20(16-7-9-18(25)10-8-16)13-19-11-12-22(24)27(19)2/h3-10,14,19-20,22,24H,11-13H2,1-2H3/t19-,20+,22+,24-/m0/s1
| Molecular Formula | C24H25ClN2O |
| Molecular Weight | 392.921 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
RTI-336 was developed as a selective dopamine transporter (DAT) inhibitor. It is known that DAT inhibitors have been developed as a promising treatment approach for cocaine dependence. RTI-336 can be a useful adjunct in the treatment of cocaine dependence because preclinical data has shown that this drug inhibits DAT with a slower onset and offset rate than cocaine and with less abuse potential and psychomotor stimulant activity. RTI-336 participated in phase I clinical trial where it showed the excellent safety and tolerability, and thus further studies in humans are warranted.
